fig2

Figure 2. Survival, ALI/AKI, and ECMO weaning curves according to IVIG use. (A) Kaplan-Meier survival curves in the overall FM cohort (n = 316). (B) Kaplan-Meier survival curves in methylprednisolone-treated patients (n = 244). (C) Kaplan-Meier survival curves in methylprednisolone-treated patients without mechanical circulatory support (MCS; n = 64). (D) Kaplan-Meier survival curves in methylprednisolone-treated patients with MCS (n = 180). (E) Aalen-Johansen cumulative incidence of ALI and/or AKI in the overall cohort. (F) Aalen-Johansen cumulative incidence of ALI/AKI in methylprednisolone-treated patients without MCS. (G) Aalen-Johansen cumulative incidence of ALI/AKI in methylprednisolone-treated patients with MCS. (H) Aalen-Johansen cumulative incidence of successful ECMO weaning with survival to discharge in all ECMO-supported patients (n = 79). (I) Aalen-Johansen cumulative incidence of successful ECMO weaning with survival to discharge in ECMO-supported patients receiving methylprednisolone (n = 73). ALI/AKI was defined as persistent alanine aminotransferase or aspartate aminotransferase elevation > 3 times the upper limit of normal and/or Kidney Disease: Improving Global Outcomes (KDIGO)-defined AKI; all patients receiving continuous renal replacement therapy were classified as having AKI. For (E-G), in-hospital death before ALI/AKI and discharge alive without prior ALI/AKI were treated as competing events. For (H and I) time zero was ECMO cannulation and death before qualifying for successful ECMO weaning was treated as a competing event. Displayed P values are from log-rank tests for (A-D) and Gray's tests for (E-I). Patients discharged alive in (A-D) were censored on their actual discharge dates, and the displayed numbers at risk were generated directly from the same survival objects used to estimate the Kaplan-Meier curves.